COPD
Conditions
Keywords
COPD, Statins, Cytokines
Brief summary
Airway inflammation is partly driven by Th17 and Th17-polarizing cytokines that is steroid-resistant. Statins could suppress IL-17 cytokines in other diseases such as atherosclerosis and multiple sclerosis in mouse model. The investigators hypothesize that statins might provide anti-inflammatory benefit of suppressing IL-17 cytokines in COPD patients.
Interventions
DRUGsimvastatin, placebo
Sponsors
Mahidol University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
35 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Stable COPD without an exacerbation within 3 months prior to study entry * mild, moderate and severe COPD with or without treatments, regardless of COPD medications
Exclusion criteria
* Concomitant other chronic lung diseases including with TB and malignancy * HIV * Being on immunosuppressive drugs and systemic corticosteroids * Dyslipidemic patients with recent cardiovascular or cerebrovascular disease within 6 month prior to study entry * Cognitive impairment * Currently on macrolides, azole anti-fungal agents, amiodarone and amlodipine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sputum cytokines | Up to 4 weeks |
Secondary
| Measure | Time frame |
|---|---|
| FEV1 | Up to 4 weeks |
| Sputum neutrophils | Up to 4 weeks |
Countries
Thailand
Outcome results
None listed